Kornimate/medical-research-clean huggingface dataset:
prospective study on power prenatal vitamins for males on yo score at-home sperm test results

Conditions: Spermatogenesis and Semen Disorders; Infertility, Male

Summary: male factor infertility is a leading cause of primary and secondary infertility. poor sperm quality is defined as having an abnormal semen analysis. there are now options to assess sperm quality with at-home sperm analysis kits, including an fda approved yo sperm kit (https://yospermtest.com/) which analyzes the motile sperm concentration \[concentration (millions / ml) x motility (percentage motile)\] and sperm quality (yo score) which compares your results to laboratory standards and to other men who have fathered children. the effects of supplements (vitamins, minerals, and anti-oxidants) on improving sperm quality are still debated. taking additional supplements to improve sperm quality represent a modifiable risk-factor that would be an easy intervention for patients struggling with male factor infertility. the life cycle of sperm production is estimated at 3 months, so any intervention would require a 3 month course to see its full effect. the investigators hypothesize that a 90 day course of the "power prenatal for sperm", a male fertility supplement by bird\&be (https://birdandbe.com/the-power-prenatal-for-sperm) will improve sperm quality (yo score) after taking the supplements.

male patients that used the fda approved yo sperm at-home sperm analysis kit, and were identified with a low yo score result (20-40) will be potential candidates for this study. an automated message about a potential research study for patients with a low yo score results (20-40) will be sent to yo sperm users. interested participants will sign up to learn more about the research study. they will be prompted to complete further screening questions to ensure they're eligible study candidates (including inclusion and exclusion criteria, as well as primary residence country and province / state). all study participants will be provided with irb-approved study information materials and informed consent documents. once approved, and consented to participate, they will receive 3 months of the power prenatal for males (https://birdandbe.com/collections/male-fertility/products/power-prenatal-vitamins-for-males) and re-evaluate the yo score results monthly for 3 consecutive months after starting the supplements. the monthly yo scores will be compared between baseline, month 1, month 2 and month 3. yo sperm's app will enable study participants to share results (yo score) with the research team at each assessment. all data will be stored by the study sponsor in a secure and private manner compliant with hipaa.

Eligibility criteria:
inclusion criteria: * male patients with at-home yo sperm score between 20-40, corresponding to a msc (motile sperm concentration) between 14-39 motile million / ml * ages 18-50 * living in usa or canada exclusion criteria: * active smokers * a known cause of male infertility (eg diagnosed varicocele, hormonal issue, history of testicular surgery, history of chemotherapy, etc) * not concurrently taking other forms of prenatal vitamins
can the electronic nose smell covid-19 antibodies?

Conditions: SARS-CoV Infection; Covid19

Summary: corona virus disease (covid-19), spread worldwide and has become an emergency of major international concern. in march 2020, the who declared the covid-19 outbreak a global pandemic. accurate and fast diagnosis is crucial in managing the pandemic. current diagnostic approaches raise several difficulties: they are time-consuming, expensive, invasive, and most important lacking high sensitivity. the gold standard diagnostic test for covid-19, reverse transcription polymerase chain reaction (rt-pcr), is highly dependent on adequate deep sampling of the swab in the naso- and oropharynx. a new diagnostic test that can correctly and rapidly identify infected patients and asymptomatic carriers is urgently required to prevent further virus transmission and thus reduce mortality rates. aim: this proof-of-principle study aims to investigate if an electronic nose (aeonose) can distinguish individuals with antibodies from individuals without antibodies against covid-19 based on analysis of volatile organic compounds (vocs). methods: between april and july 2020, persons undergoing rt-pcr and a serology test for covid-19 were recruited at maastricht umc+ for breath analysis. all participants had to breathe through the aeonose for five consecutive minutes. the voc pattern in their exhaled breath was then linked to the matching rt-pcr and serological test results.


Eligibility criteria:
inclusion criteria: * participants of whom an oropharyngeal and nasopharyngeal swab was collected for rt-pcr and on whom serology testing for the detection of antibodies was performed. exclusion criteria: * participants who where experiencing dyspnea or needed supplemental oxygen.

Keywords: electronic nose volatile organic compounds diagnosis serology antibodies
gefitinib in the treatment of the first relapse of prostate cancer beyond prostatectomy or radiotherapy

Conditions: Prostate Cancer

Summary: to evaluate activity of gefitinib in subjects with relapsed prostate cancer by estimating psa response rate at study closure


Eligibility criteria:
inclusion criteria: * relapsed prostate cancer after prostatectomy or radiotherapy * psa levels below 10 ng/ml * lymph node negative * metastasis negative * withdrawal of hormone therapy at least 6 months before entry into the study * written informed consent exclusion criteria: * metastatic disease * hormonal treatment 6 months before study entry * concomitant radiotherapy, surgery and/or chemotherapy * ild

Keywords: cancer of the prostate
phase 2a study for pk/pd of nc-001

Conditions: CHRONIC HYPONATREMIA

Summary: chronic euvolemic hyponatremia


Eligibility criteria:
inclusion criteria: 1. men or women ≥18 and ≤85 years of age 2. diagnosis of chronic euvolemic hyponatremia exclusion criteria: * 1. hyponatremia assessed by the investigator to be hypervolemic, hypovolemic, or due to psychogenic polydipsia
preoperative vaginal dinoprostone prior to abdominal myomectomy

Conditions: Myomectomy

Summary: the aim of the study is to compare the effectiveness of vaginal dinoprostone 3 mg versus placebo before myomectomy to decrease blood loss during and after the operation.


Eligibility criteria:
inclusion criteria: * • patients presenting for abdominal myomectomy with documented uterine fibroids on pelvic imaging * age ≥ 18 years and ≤ 50 years * pre-operative hemoglobin \>8 g/dl * ability to understand and the willingness to sign a written informed consent. * admissible medical/surgical history * five or less symptomatic uterine myomas * all myomas are subserous or intramural. * uterine size less than 24 weeks pregnancy exclusion criteria: * • patients who have had a prior abdominal myomectomy * post-menopausal women * patients with known bleeding/clotting disorders * patients with a history of gynecologic malignancy * hypertension. * cardiac and pulmonary diseases. * obesity (body mass index \> 30 kg/m2). * history of allergic reactions attributed to misoprostol * cases that will require intraoperative conversion of myomectomy to hysterectomy.
magnesium, vitamin b2, feverfew, andrographis paniculata and coenzyme q10 for episodic migraine prophylaxis

Conditions: Migraine

Summary: to investigate efficacy and safety of a supplementation with a fixed combination of magnesium, vitamin b2, feverfew, andrographis paniculata and coenzyme q10 (vivinor®) in episodic migraine prevention, by an observational, prospective real-world study in 113 greek patients with episodic migraine that were prospectively followed-up for three months. the primary endpoint was the change in monthly migraine days between baseline period (bl)and the third month of treatment (t3).

to investigate efficacy and safety of a supplementation with a fixed combination of magnesium, vitamin b2, feverfew, andrographis paniculata and coenzyme q10 (vivinor®) in episodic migraine prevention. an observational, prospective real-world study. after a one-month baseline period, vivinor® was introduced in 113 greek patients with episodic migraine that were prospectively followed-up for three months. the primary endpoint was the change in monthly migraine days between baseline period (bl)and the third month of treatment (t3). secondary endpoints included changes in mean intensity of migraine and in days with use of acute migraine medications. changes in scores of migraine disability assessment questionnaire (midas), headache impact test-6 (hit-6), migraine therapy assessment questionnaire (mtaq), msq-qol (migraine-specific quality of life questionnaire), hads (hospital anxiety and depression scale) were also evaluated. those with ≥50% reduction in monthly migraine days during t3 compared to bl were considered vivinor®-responders.

Eligibility criteria:
inclusion criteria: * established diagnosis of episodic migraine with or without aura for more than one year prior to study entry * evidence of 4-14 migraine days per month during the last trimester prior to screening * participants may had been either treatment- naive or not suitable for or had failed previous migraine pharmacological prophylactic treatments * were able to fully understand protocol and study information provided by the investigators. * enrolled patients should take no other preventive treatment or use any other migraine prophylactic method during the three months before entering the study and throughout the study period. exclusion criteria: * older than 50 years of age at migraine onset * evidence of moh * pregnant or nursing females * history of tension-type, cluster or hemiplegic headache * history of severe anaphylactic reactions to any of the intervention's ingredients * evidence of severe systemic diseases * history or evidence of major psychiatric disorder.

Keywords: episodic migraine supplement vivinor magnesium vitamin b2 andrographis paniculata coenzyme q10
cuff(sz): the cuff size blood pressure measurement trial

Conditions: Hypertension; Blood Pressure; Cardiovascular Diseases; Cardiovascular Risk Factor

Summary: to determine the impact of overcuffing (using a too-large cuff) and undercuffing (using a too-small cuff) on initial bp and average bp measurements when using an automated bp device, overall and stratified by appropriate cuff size to determine if the impact over- or under-cuffing differs based on the following patient characteristics: 1. hypertensive (≥140/90 based on triplicate measures using appropriately sized cuff) vs. non-hypertensive. 2. arm circumference (continuous) 3. obesity status

the investigators propose a cross-sectional study of adult participants recruited from the community. enrolled participants will have 2-3 sets of three automated bps measured, each set with a different cuff size. to accomplish this, the investigators will utilize a 2-3 period cross-over design: • two or three different periods with 3 automated bp measurements, using a bp cuff that is: * appropriately sized based on mid-upper arm circumference ( standard) * too small (one size lower than appropriate) * too large (one size higher than appropriate) individuals in whom the smallest available cuff (small adult) and largest available cuff (extra-large cuff) is appropriate for their arm circumference will only be able to undergo two periods of bp measurements.

Eligibility criteria:
inclusion criteria: * 18-80 exclusion criteria: * presence of the following on both arms: rashes, gauze dressings, casts, edema, paralysis, tubes, open sores or wounds, withered arms, a-v shunts, or if blood has been drawn from arm within last week. * being mentally impaired, pregnant. * arm circumference exceeding 50 cm.
permissive intrapartum glucose control

Conditions: Gestational Diabetes; Pregestational Diabetes

Summary: the purpose of this study is to assess whether permissive intrapartum glycemic control compared to usual care would lead to similar rate of neonatal hypoglycemia among people with diabetes.


Eligibility criteria:
inclusion criteria: * singleton gestation * presenting for intrapartum management (induction, labor, augmentation) * any diagnosis of type 1 diabetes mellitus(t1dm), type 2 diabetes mellitus (t2dm), or gestational diabetes * english or spanish fluency exclusion criteria: * major fetal anomalies affecting glucose metabolism * multiple gestation * incarcerated subjects * less than 34 weeks gestation of pregnancy * planned cesarean delivery * utilizing insulin pump during labor * stillbirth * presenting in diabetic ketoacidosis(dka)

Keywords: diabetes mellitus
a scandinavian non-interventional study of adherence to rebismart administered rebif new formulation (rnf) treatment in relapsing remitting multiple sclerosis (rrms) subjects

Conditions: Relapsing Remitting Multiple Sclerosis (RRMS)

Summary: the primary objective is to determine adherence to rebif® new formulation administered by rebismart during 12 weeks of therapy in patients with rrms.


Eligibility criteria:
inclusion criteria: * males and females between 18 and 65 years of age * have relapsing-remitting multiple sclerosis (rrms) according to the revised mcdonald criteria (2005) * having an expanded disability status scale (edss) of less than 6 at the screening visit or within 2 months prior to the screening visit * stable treatment (defined as treatment after titration period) with rebismart administered rebif new formulation (rnf) 22/44 mcg subcutaneously thrice a week for a minimum of 4 weeks prior to inclusion * previously treated with disease modifying drugs (dmds) for a minimum of 6 months prior to the screening visit * female subjects must be neither pregnant nor breast-feeding and must lack child-bearing potential as defined by either: * post-menopausal or surgically sterile; or * using a highly effective method of contraception for the duration of the study. this is defined as a method that results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly , and includes for instance implants, injectables, combined oral contraceptives, intra-uterine device (iud), sexual abstinence or vasectomized partner * have a scheduled visit 12 weeks after the inclusion visit * willing and able to comply with the protocol for the duration of the study * have given written informed consent exclusion criteria: * have had a relapse within 30 days prior to the first visit * have any contra-indications to treatment with interferon-beta 1a according to summary of product characteristics * have any other significant disease that in the investigator's opinion would exclude the subject from the trial

Keywords: relapsing remitting multiple sclerosis rebismart rebif adherence
the ideal sequence of hybrid coronary revascularization with endoscopic coronary revascularization

Conditions: Coronary Artery Disease

Summary: hybrid coronary revascularization (hcr), a combination of coronary artery bypass graft surgery (cabg) and percutaneous coronary intervention (pci), has emerged as an alternative treatment for multivessel coronary artery disease patients. however, the ideal sequence (pci or cabg) is unclear. the overall aim of this study is to investigate the best sequence within hybrid coronary revascularization using endoscopic coronary bypass grafting (i.e., first cabg then pci versus first pci then cabg)

hybrid coronary revascularization (hcr) is an emerging approach for multivessel coronary artery disease (mvd) which combines the excellent long-term outcomes of surgery with the early recovery and reduced short-term complications of percutaneous coronary intervention (pci). however, the best sequence within hybrid coronary revascularization remains unclear. when cabg is performed first (standard hcr), incomplete revascularization can cause acute coronary events in the interim period. on the other hand, when pci is performed first (reverse hcr), bleeding risks may be higher since cabg should be performed on uninterrupted dual anti-platelet therapy (dapt). the use of minimally invasive surgery techniques is associated with reduced bleeding because of the less surgical trauma and may offer the opportunity to perform reverse hcr due to the possibility to reduce the risk of bleeding. the overall aim of this study is to investigate the best sequence within hybrid coronary revascularization using endoscopic coronary bypass grafting (i.e., first cabg then pci versus first pci then cabg, figure 1)

Eligibility criteria:
inclusion criteria: * multivessel coronary disease, defined as ≥ 50% diameter stenosis by visual estimation in 2 or more of the three major epicardial vessels or major side branches, with at least one or more one stenosis amenable to revascularization with pci, if the patient cannot be full revascularized by surgery for a specific reason as determined by the heart team. patients with a non-dominant right coronary artery may be included if the left anterior descending artery (lad) and left circumflex have ≥50% stenosis. * age 18-85 * willing and able to provide informed, written consent exclusion criteria: * requirement for other cardiac or non-cardiac surgical procedures (e.g., valve replacement, carotid revascularization) * cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support at the time of randomisation * left main coronary artery disease * contraindication for dual antiplatelet therapy * st-elevation myocardial infarction (stemi) * previous cardiac surgery * participation in other interventional clinical trials * recent coronary intervention (pci) * ongoing high risk non-st-segment elevation acute coronary syndrome (acs) * life expectancy \< 1 year * active bleeding more or equal to barc 2 at time of randomisation * requiring renal replacement therapy * undergoing evaluation for organ transplantation

Keywords: hybrid coronary revascularization coronary revascularization
a phase 1 study of shr-a2102 in subjects with advanced solid tumors.

Conditions: Advanced Or Metastatic Solid Tumor Malignancies

Summary: this is a first in human, open-label, single-arm, multicenter dose escalation and expansion phase 1 study of shr-a2102 in patients with advanced or metastatic solid tumors. the purpose of this study is to assess the tolerability, safety, pharmacokinetics and immunogenicity of shr-a2102 and preliminary anti-tumor efficacy


Eligibility criteria:
inclusion criteria: 1. ability to understand and the willingness to sign a written informed consent document； 2. aged ≥18 years old; 3. histologically or cytologically confirmed advanced or metastatic malignant tumor; 4. presence of at least one measurable lesion in agreement to recist criteria; 5. eastern cooperative oncology group (ecog) performance status 0 to 1; 6. life expectancy ≥3 months; 7. adequate organ performance based on laboratory blood tests; 8. women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. exclusion criteria: 1. previous received anti-cancer systemic therapy including chemo-therapy, radiation therapy, target therapy or immuno-therapy within 4 weeks before the first dose; 2. previous received experimental medication or therapy within 4 weeks before the first dose; 3. previous therapeutic surgery within 4 weeks; 4. has unresolved toxicities from previous anticancer therapy, defined as toxicities not yet resolved to nci-ctcae version 5.0 grade ≤ 1. 5. known allergic to any compound of shr-a2102; 6. patients with uncontrolled or active brain metastasis； 7. patients with clinical significant lung disease; 8. patients with history of autoimmune diseases; 9. known active hepatitis b or c infection; 10. other serious accompanying illnesses, which, in the investigator's assessment, could seriously adversely affect the safety of the treatment.
safety profile of the combination of levosimendan and iv beta blocker in cardiogenic shock: a retrospective study

Conditions: Cardiogenic Shock; Arrythmia

Summary: the purpose of this study is to assess the safety profile of the combination of levosimendan and beta blocker in cardiogenic shock with arrythmia.


Eligibility criteria:
inclusion criteria: * adult patients admitted to the icu for cardiogenic shock who received esmolol or landiolol within 7 days of a levosimendan treatment exclusion criteria: * patient's opposition
acute exposure of simulated hypoxia on cardiac output

Conditions: Pulmonary Hypertension

Summary: randomized crossover trial in patients with pulmonary hypertension (pah, cteph) to assess the acute response to simulated altitude (fio2: 15.1% = equivalent to 2500m above sea level) on non-invasive cardiac output assessments by finapres® "nova" technology at rest and under exercise.

low altitude baseline measurements will be performed in zurich (470m asl) including echocardiography, right heart catheterization, six-minute walk test (6mwt), pulmonary function test, clinical assessment and blood gas analysis at rest and under exercise. randomly assigned to the order of testing, the participants will be tested under simulated altitude (fio2: 15.1% with the "amc altitrainer") and shamed altitude with the same device. during the exposure to simulated altitude (fio2: 15.1%) and shamed altitude of 1 hour each, the participants cardiac output non-invasively assessed will be measured throughout the whole intervention.

Eligibility criteria:
inclusion criteria: * informed consent * ph diagnosed according to internation guidelines: mean pulmonary artery pressure (mpap) ≥ 25 mmhg along with a pulmonary artery wedge pressure (pawp) ≤15 mmhg during right heart catheterization at the time of initial diagnosis * ph class 1 (pah) or 4 (cteph) * stable condition, on the same medication for \> 4 weeks * patient live permanently at an altitude \< 1000m asl. exclusion criteria: * resting partial oxygen pressure (pao2) ≤7.3 kilopascal (kpa) corresponding to the requirement of long-term oxygen therapy \> 16hour daily (nocturnal oxygen therapy alone is allowed) * severe daytime hypercapnia (pco2 \> 6.5 kpa) * susceptibility to high altitude related diseases (ams, high altitude pulmonary edema (hape), etc.) based on previous experienced discomfort at altitudes. * exposure to an altitude \>1500m for ≥3 nights during the last 4 weeks before the study participation * residence \> 1000m above sea level * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurological or orthopedic problems with walking disability * women who are pregnant or breast feeding

Keywords: simulated altitude exercise non-invasive cardiac output